Nascent Biotech Inc.
company.status.inactiveCIK 1622057fmd_1AZJZ7DFF50W72WTD38FQRYGPTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2013 to Jun 30, 2024, 43 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 3 | – | 0 | 0 | 1 | 1 | 0 | – |
| Research and development | (2) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 0 | 4 | 2 | 1 | – | – | – | – | – | – |
| Total operating expenses | – | – | – | – | – | – | 2 | 1 | 2 | 2 |
| Operating income | (2) | (4) | 1 | (2) | (1) | (3) | (1) | (0) | (2) | (2) |
| Non-interest expense | – | – | – | – | 0 | 0 | – | – | – | – |
| Interest expense | 0 | 0 | 0 | – | 0 | 0 | 0 | 0 | 2 | 0 |
| Other non-operating income (expense) | (0) | (0) | (0) | 0 | 0 | (1) | 0 | (0) | (1) | 0 |
| Income before taxes | – | (4) | 1 | (2) | (1) | (4) | – | – | – | – |
| Income tax expense | – | – | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | 1 | – | (1) | (4) | – | – | – | – |
| Net income | (2) | (4) | 1 | (2) | (1) | (4) | (1) | (0) | (3) | (2) |